People · Operator
Named in public records as an officer, director or promoter · active 2013–2023 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Guardant Health, Inc. | — | Biotechnology | Series D+ | $500.0M | $13.2B | 2013 |
| Paradromics, Inc. | — | Other Health Care | Series C | $96.9M | $570.0M | 2023 |
Helmy Eltoukhy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Helmy Eltoukhy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Samir Kaul | 1 | 32 |
| Dakin Sloss | 1 | 9 |
| Aaref Hilaly | 1 | 6 |
| Amy Kruse | 1 | 4 |
| Michael Wiley | 1 | 4 |
| Ron Kelly | 1 | 3 |
| Thomas Krummel | 1 | 3 |
| Adam Kablanian | 1 | 3 |
| Zia Huque | 1 | 3 |
| James Burrows | 1 | 2 |
| AmirAli Talasaz | 1 | 2 |
| Warren Hogarth | 1 | 2 |
| Yifan Kong | 1 | 1 |
| Matthew Angle | 1 | 1 |
| Enkelejda Bashllari | 1 | 1 |
| Court Westcott | 1 | 1 |
| Thomas R Krummel | 1 | 1 |
| Matthew R Angle | 1 | 1 |
| Ron R Kelly | 1 | 1 |
| Samir Kaur | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.